PMID: 42076099
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.
Neumann Joachim, Kirchhefer Uwe, Hofmann Britt et al.
Pharmaceutics · 2026
Research Library
Orforglipron
52 papers indexed
PMID: 42296503
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Damen Johanna A A, Idema Demy L, Vernooij Robin W M et al.
Annals of internal medicine · 2026
PMID: 42092956
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.
Schnell Oliver, Agarwal Arnav, Azizi Michel et al.
Cardiovascular diabetology · 2026
PMID: 41992023
Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.
Lu Ying, Chen Jiajie, Guo Yuqing et al.
Diabetes, obesity & metabolism · 2026
PMID: 41933725
Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
Mishra Nikunja Kishor
Clinical nutrition ESPEN · 2026
PMID: 42399716
Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.
Morse Bridget L, Coutant David E, Ma Xiaosu et al.
Clinical pharmacology and therapeutics · 2026
PMID: 41728423
Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
Tantoush Marwan, Almaghrabi Yaseen, Abusbaeh Allaeddin et al.
Cureus · 2026
PMID: 42403733
Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.
Castro-Gamboa José, Mora-Jiménez Jeaustin, Arguedas-Chacón Sebastián et al.
Cureus · 2026
PMID: 42419792
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong Kailei, Shi Qingyang, Xie Xinran et al.
BMJ (Clinical research ed.) · 2026
PMID: 42198313
Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.
Paceana Maria-Alexandra, Tartau Liliana Mititelu, Boboc Ianis Kevyn Stefan et al.
Pharmaceutics · 2026
PMID: 42305200
Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron.
Li Mengya, Fang Jiahui, Qi Gaoguo et al.
ACS medicinal chemistry letters · 2026
PMID: 42394981
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
Wu Xichao, Yang Yujiao, Cui Xueyan et al.
Frontiers in pharmacology · 2026
PMID: 41765029
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Rosenstock Julio, Yabe Daisuke, Cox David et al.
Lancet (London, England) · 2026
PMID: 42363271
Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.
Emara Ahmed, Emara Mohamed, Mansour Ahmed et al.
Diabetology & metabolic syndrome · 2026
PMID: 41715239
Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.
Alper Adir, Peleg Gal, Fagin Adina et al.
Cardiovascular diabetology. Endocrinology reports · 2026
PMID: 42458197
Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.
Alper Adir, Fagin Adina, Karthikeyan Aditya et al.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
PMID: 42433749
Fast-tracked innovation: orforglipron approval under the FDA's National Priority Voucher program.
Sheikh Mahnoor, Fatima Syeda Habiba, Bilal Zaibunnisa et al.
Annals of medicine and surgery (2012) · 2026
PMID: 42338042
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.
Wharton Sean, Stefanski Adam, Chen Jiaxun et al.
Diabetes, obesity & metabolism · 2026
PMID: 42224699
In T2D inadequately controlled with metformin, orforglipron reduced HbA 1c more than oral semaglutide at 52 wk.
Lau Darren, ACP Journal Club Editorial Team at McMaster University
Annals of internal medicine · 2026
PMID: 42568490
Incretin analogues as cardiovascular agents: a state-of-the-art review.
Araiza-Garaygordobil Diego, Rico-Fontalvo Jorge, Hernández-Balbuena Betsabe et al.
Frontiers in endocrinology · 2026
PMID: 42562129
Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
Narla Shanthi, Narla Radhika R
Clinics in dermatology · 2026
PMID: 42483679
Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.
Li Li, Shui Dianpeng, Zhang Xiong et al.
Frontiers in endocrinology · 2026
PMID: 42251768
Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.
Gadde Kishore M, Talebloo Jonanne, Heymsfield Steven B
JAMA · 2026
PMID: 42418948
Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.
Li Yufeng, Sheng Hongda, Zhou Tingting et al.
Drug metabolism and disposition: the biological fate of chemicals · 2026
PMID: 42487237
Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.
Hageen Ahmed W, Gadelmawla Ahmed Farid, Saleh Ahmad Omar et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 41984238
Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron.
Imran Raafey, Imran Manahil, Roshan Muhammad
Acta diabetologica · 2026
PMID: 41948476
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Lempesis Ioannis G, Dalamaga Maria
Metabolism open · 2026
PMID: 41742335
Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS.
Vafeidou Kyriaki, Koufakis Theocharis, Stavropoulos Konstantinos et al.
Expert review of endocrinology & metabolism · 2026
PMID: 41870800
Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.
Odeleye Victoria, Singh Nikita, Gautam Swotantra et al.
Current cardiology reports · 2026
PMID: 42225305
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
Michalak Wojciech, Bøg Martin, Bendixen Theiss et al.
Diabetes, obesity & metabolism · 2026
PMID: 41939723
Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage.
Niazi Sarfaraz K
Frontiers in drug delivery · 2026
PMID: 42139026
Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
The Medical letter on drugs and therapeutics · 2026
PMID: 42420063
Orforglipron (Foundayo) for adults with obesity.
Zhou Qingtong, Li Guanyi, Wang Ming-Wei
Trends in pharmacological sciences · 2026
PMID: 42251766
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary.
JAMA · 2026
PMID: 42251769
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
Giorgino Francesco, D'Souza Sherwin, Ludwig Lisa et al.
JAMA · 2026
PMID: 42138709
Orforglipron Calcium.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
PMID: 42508653
Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling.
Deng Yong, Guo Zhiyi, Yu Lichun et al.
Biochemical pharmacology · 2026
PMID: 42138103
Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.
Zaman Wajid, Amin Adnan
Expert opinion on pharmacotherapy · 2026
PMID: 42259339
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Welch Michelle, Forst Thomas, Jia Weiping et al.
Lancet (London, England) · 2026
PMID: 42120723
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Aronne Louis J, Horn Deborah B, le Roux Carel W et al.
Nature medicine · 2026
PMID: 42577069
Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.
Horn Deborah B, Shukla Alpana P, Huang Haocheng et al.
Obesity pillars · 2026
PMID: 42383207
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.
Malhotra Atul, Gottlieb Daniel J, Kundel Vaishnavi et al.
Contemporary clinical trials communications · 2026
PMID: 42505410
Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects.
Li Yazhou, Glotfelty Elliot J, Parekh Pathik et al.
Cells · 2026
PMID: 41683830
Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.
Kansakar Urna, Jankauskas Stanislovas S, Pande Shivangi et al.
International journal of molecular sciences · 2026
PMID: 42479349
Orforglipron: First Approval.
Shirley Matt
Drugs · 2026
PMID: 41994902
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
Ma Xiaosu, Li Ying Grace, Raha Sohini et al.
Diabetes, obesity & metabolism · 2026
PMID: 42244474
Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.
Heisey Henry D, Gregg L Parker, Verrico Christopher D et al.
Diabetes, obesity & metabolism · 2026
PMID: 42564827
Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
Kamrul-Hasan A B M, Ashraf Hamid, Nagendra Lakshmi et al.
Obesity science & practice · 2026
PMID: 42153087
Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.
Patel Digantkumar
Cureus · 2026
PMID: 42116665
The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
Hageen Ahmed W, Gadelmawla Ahmed Farid, Saleh Ahmad Omar et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 42556625
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
Roskoski Robert
Pharmacological research · 2026
PMID: 42437645
Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.
Mohammad Anwar, Dashti Mohammed, Malik M D Zubbair et al.
International journal of biological macromolecules · 2026
For research use only. This index links to third-party literature. Nothing here constitutes medical advice.